GridAI Technologies Corp Com (New) 2025 (GRDX:NASDAQ) closed at $5.55 on October 26, 2026, down 0.98% on the day. The stock trades 19.9% below its 52-week high of $6.93 and 196.8% above its 52-week low of $1.87. Over the past year, it gained 35.7%. GridAI Technologies Corp Com (New) 2025 is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, GRDX closed higher on 116 days (46%). Its best day was December 30, 2025 (+23.28%) and its worst was November 19, 2025 (-19.88%). The stock moved 10% or more in a single session 52 times. It opened at least 5% above the previous day's high 2 times.
Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around its proprietary technologies, including: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for Celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Find more stocks like GRDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.